SCHEMBL21044083

SCHEMBL21044083

COC(=O)C(C)(C)c1csc(NS(=O)(=O)CC(C)C)n1

nearest known ligand 0.39

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
CTPS1 P17812 3/20 0.39
CTPS2 Q9NRF8 2/20 0.39
KMT2A Q03164 6/20 0.39
MEN1 O00255 4/20 0.39
ALDH1A1 P00352 3/20 0.36
HPGD P15428 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
PKM P14618 1/20 0.36
MAPT P10636 3/20 0.36
POLB P06746 2/20 0.36
LMNA P02545 1/20 0.36
RECQL P46063 1/20 0.36
CYP2C9 P11712 2/20 0.35
CYP2C19 P33261 2/20 0.35
CYP1A2 P05177 1/20 0.35
CYP3A4 P08684 1/20 0.35
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL21044437 0.88 CTPS1 (0.38) CTPS1CTPS2KMT2AMEN1ALDH1A1
SCHEMBL22869126 0.87 CTPS1 (0.44) CTPS1CTPS2KMT2AMEN1ALDH1A1
SCHEMBL21044168 0.86 CTPS1 (0.43) CTPS1CTPS2KMT2AMEN1ALDH1A1
SCHEMBL22869171 0.83 KMT2A (0.41) CTPS1CTPS2KMT2AMEN1ALDH1A1
SCHEMBL22869175 0.82 CTPS1 (0.45) CTPS1CTPS2KMT2AMEN1ALDH1A1
SCHEMBL22869127 0.82 KMT2A (0.43) CTPS1CTPS2KMT2AMEN1ALDH1A1
SCHEMBL21044009 0.81 CTPS1 (0.44) CTPS1CTPS2KMT2AMEN1ALDH1A1
SCHEMBL21044012 0.79 KMT2A (0.46) CTPS1CTPS2KMT2AMEN1ALDH1A1
SCHEMBL25099203 0.77 ALDH1A1 (0.44) CTPS1CTPS2KMT2AMEN1ALDH1A1
SCHEMBL21044015 0.77 CTPS1 (0.58) CTPS1CTPS2KMT2AMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3717459-B1 COMPOUNDS STEP PHARMA S A S (FR) 2026-01-21 EP disclosed
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 STEP PHARMA S.A.S. (FR) 2023-05-23 US disclosed
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 STEP PHARMA S.A.S. (FR) 2023-05-23 US disclosed
US-20210002269-A1 COMPOUNDS STEP PHARMA S.A.S. (FR) 2021-01-07 US disclosed
EP-3492454-A1 COMPOUNDS Step Pharma S.A.S. (FR) 2019-06-05 EP disclosed
EP-3492454-A1 COMPOUNDS Step Pharma S.A.S. (FR) 2019-06-05 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11655246-B2 Aminothiazole compounds as inhibitors of CTPS1 CTPS1, CTPS2, TBXAS1 CTPS1 1/4885CTPS2 2/4885KMT2A 4442/4885
US-20210002269-A1 COMPOUNDS UGT1A1, CYP1A1, CYP19A1 CTPS1 2385/4885CTPS2 2441/4885KMT2A 4127/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.